Depressed, older adults with diabetes live longer when they are treated for depression, according to a study in the December issue of Diabetes Care, which publishes on November 27, 2007.
Also being published this month is an editorial by U.S. Food and Drug Administration (FDA) Medical Officer Dr. Robert Misbin, highlighting lessons learned from the recent Avandia controversy and suggesting a re-evaluation of the approval process for diabetes drugs.
The depression study, which followed primary care patients in the New York City, Philadelphia and Pittsburgh areas for five years, also showed that treating depression reduced mortality more for those who had diabetes than for those who did not.
“Depression is not only common in persons with diabetes but contributes to not taking medicines, not following prescribed diets, and overall reduced quality of life,” said lead researcher Dr. Hillary R. Bogner, Assistant Professor at the Department of Family Practice and Community Medicine at the University of Pennsylvania.
Depression and diabetes are two of the most commonly treated health problems treated in primary care settings. Previous studies have drawn a link between diabetes and depression, and between the combination of the two an increased risk of premature death. This is the first known study to examine the relationship between diabetes and mortality in a depression intervention trial.
The results led researchers to conclude that better models of care should be developed that integrate depression management into the treatment of people with diabetes.
Depressed people with diabetes who received more resources for depression treatment were half as likely to die over a 5-year period compared to depressed people with diabetes who did not receive more resources for depression treatment.
Lessons from the Avandia Controversy
“The time has come to reassess what should be expected of a new drug to treat diabetes,” concludes an editorial written by Dr. Robert Misbin, a Medical Officer for the U.S. Food and Drug Administration (FDA).
The editorial suggests that the FDA “reevaluate criteria for approval of drugs to treat type 2 diabetes,” in light of the recent controversy surrounding the diabetes drug rosiglitazone (Avandia).